S. h.	Substitute for form 1449A/PTO			Complete if Known 4 7 2 PA			
300	STITLE FOL TOWN	1445/0710	•	Application Number	4 SELINDOSOSTISS 21		
IN	FORMAT	TION DISC	LOSURE	Filing Date	June 6, 2003		
		NT BY AP	•	First Named Inventor	Phillip Mark Hogarth		
•	,	,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Art Unit 1632			
			_	Examiner Name Lieto			
Sheet	. 1	of	1	Attorney Docket Number	4602AL-1		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.'	Document Number Number-kind Code 2 le knowed	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-				
		UŞ-				
		US-				
		US-				
		US				

				FOREI	GN PATENT DO			
Examiner Initials*	Cite No.'	Foreign Patent Document Country Code*: Number*: Kind Code* (if Known)			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
bi		PCT	•	WO 96/08512	03/21/1996	Austin Research Institute Cancer and Antiinflammatory Syndicate No.1		
Da		PCT	-	WO 95/28959	11/02/1995	Sloan-Kettering Institute for Cancer Research		
·			·				•	
			-					
			7-					T

	The Date of Human Se Decision Sur DIVA is the Immune Character of District A. A. Tenans is Manager
LBL :	The Date of them 5. Describes Sur Diff. to the terminal Olerand of Districts A Transmiss Manager
. 110	The Role of Human Fc Receiptor FcyRliA in the Immune Clearance of Platelets: A Transgenic Mouse Model*, McKenzie et al., The Journal Immunology, pp. 4311-4318 (1999) [16], [16]
	Functional Consequences of the Interaction Between T-cell Antigen Receptors and FcyRs on T Cells Kwack et al., Immunology Letters, 44 (1995) pp. 139-143, Elsevier Science B.V.

	1				1
Examiner Sigature	m). /		Date Considered	3/	06
*EXAMINER: Initial/i		whether armot citation is in conformance and no	ot considered. Und	oo apuk	py of this form with nex